Search Results - "Rijmers, Jamie"

ABCB1 attenuates brain exposure to the KRASG12C inhibitor opnurasib whereas binding to mouse carboxylesterase 1c influences its plasma exposure by Rijmers, Jamie, Retmana, Irene A., Bui, Viët, Arguedas, Davinia, Lebre, Maria C., Sparidans, Rolf W., Beijnen, Jos H., Schinkel, Alfred H.

“…Opnurasib (JDQ443) is a newly developed oral KRASG12C inhibitor, with a binding mechanism distinct from the registered KRASG12C inhibitors sotorasib and…”
Get full text

Pharmacokinetics of the KRASG12C inhibitor adagrasib is limited by CYP3A and ABCB1, and influenced by binding to mouse plasma carboxylesterase 1c by Loos, Nancy H.C., Retmana, Irene A., Rijmers, Jamie, Wang, Yaogeng, Gan, Changpei, Lebre, Maria C., Sparidans, Rolf W., Beijnen, Jos H., Schinkel, Alfred H.

“…Adagrasib (Krazati™) is the second FDA-approved specific KRASG12C inhibitor for non-small cell lung cancer (NSCLC) patients harboring this mutation. The impact…”
Get full text

Development and validation of an LC-MS/MS method for the quantification of KRASG12C inhibitor opnurasib in several mouse matrices and its application in a pharmacokinetic mouse study by Retmana, Irene A., Çelebi, Nefise, Rijmers, Jamie, Schinkel, Alfred H., Beijnen, Jos H., Sparidans, Rolf W.

“…•First developed bioanalytical assay for opnurasib in nine different mouse matrices.•LC-MS/MS method with protein precipitation has been successfully…”
Get full text

Brain Exposure to the Macrocyclic ALK Inhibitor Zotizalkib is Restricted by ABCB1, and Its Plasma Disposition is Affected by Mouse Carboxylesterase 1c by Rijmers, Jamie, Sparidans, Rolf W., Acda, Manon, Loos, Nancy H. C., Epeslidou, Emmanouela, Bui, Viët, Lebre, Maria C., Tibben, Matthijs, Beijnen, Jos H., Schinkel, Alfred H.

“…Zotizalkib (TPX-0131), a fourth-generation macrocyclic anaplastic lymphoma kinase (ALK) inhibitor, is designed to overcome resistance due to secondary ALK…”
Get full text

Development and validation of an LC-MS/MS method for the quantification of KRAS G12C inhibitor opnurasib in several mouse matrices and its application in a pharmacokinetic mouse study by Retmana, Irene A, Çelebi, Nefise, Rijmers, Jamie, Schinkel, Alfred H, Beijnen, Jos H, Sparidans, Rolf W

“…Opnurasib (JDQ-443) is a highly potent and promising KRAS inhibitor that is currently under clinical investigation. Results of the ongoing clinical research…”
Get full text

Interplay of Ritonavir-Boosted Oral Cabazitaxel with the Organic Anion-Transporting Polypeptide (OATP) Uptake Transporters and Carboxylesterase 1 in Mice by Loos, Nancy H.C., Ferreira Martins, Margarida L., Rijmers, Jamie, de Jong, Daniëlle, Lebre, Maria C., Tibben, Matthijs, Beijnen, Jos H., Schinkel, Alfred H.

“…Intravenously administered chemotherapeutic cabazitaxel is used for palliative treatment of prostate cancer. An oral formulation would be more patient-friendly…”
Get full text

TRSC-06 CHARACTERIZATION OF A NON-SMALL CELL LUNG CANCER ROS1-FUSION BRAIN METASTASIS MODEL by Rijmers, Jamie, Bui, Viët, Heijningen, Caroline van, Lebre, Maria, Tellingen, Olaf van, Beijnen, Jos, Schinkel, Alfred

“…Abstract BACKGROUND Non-small cell lung cancer (NSCLC) represents 85 percent of all lung cancers. Among NSCLC patients, 1-2 percent harbor mutations in the…”
Get full text

ABCB1 attenuates brain exposure to the KRAS G12C inhibitor opnurasib whereas binding to mouse carboxylesterase 1c influences its plasma exposure by Rijmers, Jamie, Retmana, Irene A, Bui, Viët, Arguedas, Davinia, Lebre, Maria C, Sparidans, Rolf W, Beijnen, Jos H, Schinkel, Alfred H

“…Opnurasib (JDQ443) is a newly developed oral KRAS inhibitor, with a binding mechanism distinct from the registered KRAS inhibitors sotorasib and adagrasib…”
Get full text